<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423174</url>
  </required_header>
  <id_info>
    <org_study_id>FMW-IT-02</org_study_id>
    <nct_id>NCT02423174</nct_id>
  </id_info>
  <brief_title>Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery</brief_title>
  <official_title>Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Domain Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Domain Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the clinical trial is to determine the suitability of the FMwand
      Ferromagnetic Surgical System for Total Mesorectal Excision Surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding
  </why_stopped>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Safety and feasibility will be assessed by evaluating intra-operative serious adverse events, if any, and their relationship with the FMwand Ferromagnetic Surgical System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Drainage</measure>
    <time_frame>Beginning day 2 after surgery and for the duration of the hospital stay, an expected average of 6 days</time_frame>
    <description>Volume of drainage and drain residence time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of urinary or fecal incontinence</measure>
    <time_frame>Beginning day 2 after surgery and for the duration of the hospital stay, an expected average of 6 days</time_frame>
    <description>Incidence of urinary or fecal incontinence attributed to post-surgical nerve dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Procedure</measure>
    <time_frame>During Procedure</time_frame>
    <description>Total operative time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of TME resection</measure>
    <time_frame>During procedure</time_frame>
    <description>Total resection time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of post-operative complications</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <description>Evaluation of pelvic fibrosis, adherences, abscess or fluid collections assessed by CT scan</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Total Mesorectal Excision</arm_group_label>
    <description>Patients with an indication for surgical intervention for a total mesorectal excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Surgical intervention with the FMwand Surgical System</description>
    <arm_group_label>Total Mesorectal Excision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FMwand Surgical System</intervention_name>
    <arm_group_label>Total Mesorectal Excision</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for surgical intervention for a total mesorectal excision
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed rectal cancer to the lower two-thirds of the rectum (higher and T2 N0 or N+)

          -  Amenable for standard surgery procedures using electrocautery, argon beam, lasers or
             other conventional tissue removal modalities

          -  ECOG status ≤ 2

          -  Life expectancy &gt;3 months

          -  Age ≥ 18 years old

          -  Age ≤ 80 years old

          -  Ability to provide written informed consent and HIPAA forms prior to admission to this
             study

          -  Willingness to meet all of the expected requirements of this clinical protocol

        Exclusion Criteria:

          -  Patient with metastasis

          -  History of radiotherapy or chemotherapy for the treatment of rectal cancer

          -  Uremia - BUN&gt;40

          -  Hemodialysis

          -  Existing urinary or fecal incontinence

          -  Pregnant or lactating

          -  Previously diagnosed coagulopathy or bleeding diathesis

          -  Currently, or within the previous 10 days prior to surgery, taking any medications
             that would produce bleeding diathesis including but not limited to, Plavix, warfarin,
             NSAIDs, clopidogrel, ticlopidine or valproic acid

          -  History of significant cardiac disorders that would necessitate special fluid
             management protocols

          -  History of acute myocardial infarction and/or acute angina

          -  INR &gt;1.4 in the 24 hours prior to surgery

          -  PTT &gt;40 in the 24 hours prior to surgery

          -  Platelet count &lt;100K in the 24 hours prior to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Izzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nationale Tumori IRCCS - Fondazione &quot;G Pascale&quot;</affiliation>
  </overall_official>
  <reference>
    <citation>Bowers CA, Burns G, Salzman KL, McGill LD, Macdonald JD. Comparison of tissue effects in rabbit muscle of surgical dissection devices. Int J Surg. 2014;12(3):219-23. doi: 10.1016/j.ijsu.2013.12.014. Epub 2014 Jan 7.</citation>
    <PMID>24406264</PMID>
  </reference>
  <reference>
    <citation>MacDonald JD, Bowers CA, Chin SS, Burns G. Comparison of the effects of surgical dissection devices on the rabbit liver. Surg Today. 2014 Jun;44(6):1116-22. doi: 10.1007/s00595-013-0712-4. Epub 2013 Sep 5.</citation>
    <PMID>24006128</PMID>
  </reference>
  <reference>
    <citation>Tok, S et al. Comparison of a Novel Thermal Surgical Technology with Monopolar and Carbon Dioxide Laser in a Rat Glioma Model. Poster presentation.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

